CONTINUOUS AND FIXED-CYCLE DOSING OF INTRAVENOUS EFGARTIGIMOD FOR GENERALIZED MYASTHENIA GRAVIS: STUDY DESIGN OF ADAPT NXT

被引：0
|
作者：
Sahagian, Gregory [1 ]
Hussain, Yessar [2 ]
Feinberg, Marc H. [3 ]
Habib, Ali A. [4 ]
Skripuletz, Thomas [5 ]
Ruck, Tobias [6 ]
Brauer, Edward [7 ]
Gelinas, Deborah [7 ]
Liu, Li [7 ]
Podhorna, Jana [7 ]
Mantegazza, Renato [8 ]
机构：
[1] Neurol Ctr Southern Calif, Carlsbad, CA USA
[2] Austin Neuromuscular Ctr, Austin, TX USA
[3] South Florida Neurol Associates, Boca Raton, FL USA
[4] Univ Calif Irvine, Dept Neurol, Irvine, CA USA
[5] Hannover Med Sch, Hannover, Germany
[6] Heinrich Heine Univ, Dept Neurol, Fac Med, Dusseldorf, Germany
[7] argenx, Ghent, Belgium
[8] Fdn IRCCS Ist Neurol Carlo Besta, Dept Neuroimmunol & Neuromuscular Dis, Milan, Italy
来源：
MUSCLE & NERVE | 2022年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S14 / S14
页数：1
相关论文
共 50 条
  • [31] Prospective cohort study evaluating efficacy and safety of efgartigimod in Chinese generalized myasthenia gravis patients
    Wang, Pan
    Zhang, Bo
    Yin, Jian
    Xi, Jianying
    Tan, Ying
    Gao, Feng
    Zeng, Fan
    Chang, Ting
    Zhou, Hao
    Liang, Hui
    Zhao, Zhongyan
    Yang, Huan
    Zhao, Chongbo
    Huang, Shixiong
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [32] Analysis of Efgartigimod Efficacy Across Patient Populations and Myasthenia Gravis Specific Scales: Results of the Phase 3 ADAPT Study
    Bril, Vera
    Murai, HIroyuki
    Vu, Tuan
    Karam, Chafic
    Peric, Stojan
    Margania, Temur
    Bilinska, Malgorzata
    Shakarishvili, Roman
    Smilowski, Marek
    Guglietta, Antonio
    Ulrichts, Peter
    Vangeneugden, Tony
    Utsugisawa, Kimiaki
    Verschuuren, Jan
    Mantegazza, Renato
    Howard, James F., Jr.
    ANNALS OF NEUROLOGY, 2021, 90 : S28 - S28
  • [33] HOSPITALIZATION AND EXACERBATION ESTIMATES OF EFGARTIGIMOD VS. CONVENTIONAL THERAPY IN GENERALIZED MYASTHENIA GRAVIS PATIENTS: A POST-HOC ANALYSIS OF THE PHASE 3 ADAPT STUDY
    Qi, C.
    Dewilde, S.
    Gelinas, D.
    Brauer, E.
    Phillips, G.
    VALUE IN HEALTH, 2022, 25 (07) : S329 - S329
  • [34] PHASE 3 TRIAL INVESTIGATING IMPACT OF INTRAVENOUS EFGARTIGIMOD IN ANTI-ACETYLCHOLINE RECEPTOR ANTIBODY NEGATIVE GENERALIZED MYASTHENIA GRAVIS
    Guptill, Jeffrey
    Jimenez, Rosa H.
    Howard, James F., Jr.
    MUSCLE & NERVE, 2024, 70 (03) : 538 - 538
  • [35] Phase 3 Trial Investigating Impact of Intravenous Efgartigimod in Anti-Acetylcholine Receptor Antibody Negative Generalized Myasthenia Gravis
    Jared
    Guptill, Jeffrey
    Jimenez, Rosa H.
    Howard, James F., Jr.
    ANNALS OF NEUROLOGY, 2024, 96 : S270 - S271
  • [36] Long-term safety, and efficacy of subcutaneous Efgartigimod PH20 in patients with generalized myasthenia gravis: interim results of ADAPT-SC
    Musick, K.
    Howard, J.
    Li, G.
    Vu, T.
    Korobko, D.
    Smilowski, M.
    Liu, L.
    Steeland, S.
    Noukens, J.
    Van Hoorick, B.
    Podhorna, J.
    Li, Y.
    Utsugisawa, K.
    Sacca, F.
    Wiendl, H.
    De Bleecker, J.
    Mantegazza, R.
    NEUROMUSCULAR DISORDERS, 2023, 33 : S179 - S179
  • [37] Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod PH20 in Patients with Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC plus Study
    Howard, James
    Li, George
    Vu, Tuan
    Korobko, Denis
    Smilowski, Marek
    Liu, Li
    Steeland, Sophie
    Noukens, Jan
    Van Hoorick, Benjamin
    Podhorna, Jana
    Li, Yuebing
    Utsugisawa, Kimiaki
    Sacca, Francesco
    Wiendl, Heinz
    De Bleecker, Jan
    Mantegazza, Renato
    NEUROLOGY, 2023, 100 (17)
  • [38] LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF SUBCUTANEOUS EFGARTIGIMOD PH20 IN PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS: INTERIM RESULTS OF THE ADAPT-SC plus STUDY
    Li, Yuebing
    Howard, James F., Jr.
    Vu, Tuan
    Korobko, Denis
    Steeland, Sophie
    Van Hoorick, Benjamin
    Podhorna, Jana
    Hodari, Moana
    Utsugisawa, Kimiaki
    Sacca, Francesco
    De Bleecker, Jan L.
    Mantegazza, Renato
    MUSCLE & NERVE, 2024, 70 (03) : 559 - 560
  • [39] Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod PH20 in Patients with Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC plus Study
    Ritt, Elissa
    Howard, James F., Jr.
    Li, George
    Vu, Tuan
    Korobko, Denis
    Smilowski, Marek
    Liu, Li
    Steeland, Sophie
    Noukens, Jan
    Van Hoorick, Benjamin
    Podhorna, Jana
    Li, Yuebing
    Utsugisawa, Kimiaki
    Sacca, Francesco
    Wiendl, Heinz
    De Bleecker, Jan L.
    Mantegazza, Renato
    ANNALS OF NEUROLOGY, 2023, 94 : S244 - S245
  • [40] Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT)
    Sacca, Francesco
    Barnett, Carolina
    Vu, Tuan
    Peric, Stojan
    Phillips, Glenn A.
    Zhao, Sihui
    Qi, Cynthia Z.
    Gelinas, Deborah
    Chiroli, Silvia
    Verschuuren, Jan J. G. M.
    JOURNAL OF NEUROLOGY, 2023, 270 (04) : 2096 - 2105
12345